Exact Sciences Corporation

At this time, I would like to welcome everyone to the ExactScience first quarter 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Note, we will only have time for one question per person. Thank you. I would now like to turn the call over to Eric Holdnick, Manager, Investor Relations. Please go ahead.

Erica, thank you for joining us for ExactScience's first quarter 2024 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, Jeff Elliott, our Chief Financial Officer, and Aaron Bloomer, Executive Vice President of Finance, who we recently announced as our next Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, will also be available for questions. Exact Sciences issued a news release earlier this afternoon detailing our first quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our FCC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

Thanks, Eric. The Exact Sciences team is off to a strong start to the year. During the first quarter, we advanced our purpose of helping to eradicate cancer by further embedding Cole Yardley's standard of care increasing adoption of Oxide DX internationally, and deepening our relationships with health systems, payers, and patients. Highlights from the first quarter include testing more than a million people globally for cancer and rare diseases, being recognized as a Gallup exceptional workplace, a prestigious award given to only 60 companies worldwide, increasing Cologuard adoption in large health systems, organized screening programs, among payers and in federally qualified health clinics. Expanding the number of Oxide DX international ordering providers by more than 20% year over year. Making progress towards moving our precision oncology portfolio onto ExactNexus, our proprietary IT platform. Launching our hereditary cancer test risk guard through our oncology channel. Announcing the New England Journal of Medicine published results of our pivotal Blue Sea study, which will support FDA approval of Cologuard Plus, and generating evidence to support future tests, including OncoDetect, our molecular residual disease test. These achievements reflect our commitment to solving the needs of patients and healthcare providers, and we're well-positioned to achieve our goals for the year. Jeff will now review our financial results for the quarter.